Silverberg Bernstein Capital Management’s Niagen Bioscience NAGE Stock Holding History

Silverberg Bernstein Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Buy	140,602 +2,500	+2%	+$10.1K	0.17%	50
2026 Q1	$609K	Buy	138,102 +6,940	+5%	+$37.5K	0.34%	46
2025 Q4	$834K	Buy	131,162 +5,900	+5%	+$41K	0.48%	42
2025 Q3	$1.17M	Buy	125,262 +25,786	+26%	+$260K	0.71%	36
2025 Q2	$1.43M	Buy	99,476 +3,939	+4%	+$38.9K	0.98%	30
2025 Q1	$659K	Buy	95,537 +15,000	+19%	+$94.3K	0.61%	38
2024 Q4	$427K	Sell	80,537 -2,720	-3%	-$14.9K	0.38%	39
2024 Q3	$304K	Buy	83,257 +1,100	+1%	+$3.46K	0.28%	41
2024 Q2	$224K	Hold	82,157	–	–	0.22%	43
2024 Q1	$286K	Sell	82,157 -600	-0.7%	-$1.11K	0.28%	41
2023 Q4	$118K	Buy	+82,757	New	+$115K	0.11%	49

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Silverberg Bernstein Capital Management's NAGE Position: Q2 2026 in Review

Silverberg Bernstein Capital Management increased its Niagen Bioscience (NAGE) stake by 1.8% in Q2 2026, buying an estimated $10.1K and bringing the position to 140,602 shares worth $449K. The position accounts for 0.17% of the portfolio, ranked #50.

Silverberg Bernstein Capital Management first reported a position in NAGE in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.43M in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Silverberg Bernstein Capital Management held 140,602 shares of Niagen Bioscience worth $449K as of Q2 2026.
Silverberg Bernstein Capital Management bought 2,500 Niagen Bioscience shares in Q2 2026, an estimated $10.1K.
Niagen Bioscience made up 0.17% of Silverberg Bernstein Capital Management's portfolio in Q2 2026, its #50 holding.
Silverberg Bernstein Capital Management first reported a position in Niagen Bioscience in Q4 2023 and has held it in 11 quarters since.
Silverberg Bernstein Capital Management's Niagen Bioscience position peaked at $1.43M in Q2 2025.
139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q2 2026, filed 7 Jul 2026.